Stone Ridge Asset Management LLC Buys New Position in PRA Health Sciences (PRAH)

Stone Ridge Asset Management LLC bought a new stake in PRA Health Sciences (NASDAQ:PRAH) in the 4th quarter, Holdings Channel reports. The firm bought 2,318 shares of the medical research company’s stock, valued at approximately $211,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. American International Group Inc. lifted its stake in shares of PRA Health Sciences by 2.1% in the 4th quarter. American International Group Inc. now owns 33,402 shares of the medical research company’s stock valued at $3,042,000 after purchasing an additional 683 shares during the period. The Manufacturers Life Insurance Company raised its position in PRA Health Sciences by 1.9% during the fourth quarter. The Manufacturers Life Insurance Company now owns 37,921 shares of the medical research company’s stock worth $3,454,000 after acquiring an additional 713 shares during the period. First Bank & Trust raised its position in PRA Health Sciences by 30.0% during the fourth quarter. First Bank & Trust now owns 3,259 shares of the medical research company’s stock worth $297,000 after acquiring an additional 752 shares during the period. Ameritas Investment Partners Inc. raised its position in PRA Health Sciences by 23.5% during the third quarter. Ameritas Investment Partners Inc. now owns 4,204 shares of the medical research company’s stock worth $325,000 after acquiring an additional 800 shares during the period. Finally, Swiss National Bank raised its position in PRA Health Sciences by 1.3% during the fourth quarter. Swiss National Bank now owns 85,358 shares of the medical research company’s stock worth $7,774,000 after acquiring an additional 1,100 shares during the period. Hedge funds and other institutional investors own 99.22% of the company’s stock.

How to Become a New Pot Stock Millionaire

PRAH has been the subject of a number of research analyst reports. Barclays initiated coverage on shares of PRA Health Sciences in a research report on Monday, December 11th. They set an “overweight” rating and a $94.00 price objective for the company. BidaskClub upgraded shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, December 14th. Mitsubishi UFJ Financial Group initiated coverage on shares of PRA Health Sciences in a research report on Friday, December 15th. They set an “overweight” rating and a $102.00 price objective for the company. Finally, Zacks Investment Research cut shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $95.67.

Shares of NASDAQ PRAH opened at $81.38 on Friday. The stock has a market capitalization of $5,325.90, a PE ratio of 25.43, a price-to-earnings-growth ratio of 1.31 and a beta of 0.49. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 1.31. PRA Health Sciences has a 52 week low of $61.93 and a 52 week high of $95.90.

PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, February 21st. The medical research company reported $1.04 EPS for the quarter, beating the Zacks’ consensus estimate of $1.02 by $0.02. The business had revenue of $568.80 million during the quarter, compared to analysts’ expectations of $543.78 million. PRA Health Sciences had a net margin of 3.85% and a return on equity of 22.77%. The company’s quarterly revenue was up 37.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.71 earnings per share. equities research analysts predict that PRA Health Sciences will post 3.81 EPS for the current fiscal year.

In other news, VP Linda Baddour sold 67,000 shares of the stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $90.27, for a total value of $6,048,090.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.10% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3337768/stone-ridge-asset-management-llc-buys-new-position-in-pra-health-sciences-prah.html.

PRA Health Sciences Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

1st Source  Expected to Announce Quarterly Sales of $76.80 Million
1st Source Expected to Announce Quarterly Sales of $76.80 Million
PDC Energy  Scheduled to Post Earnings on Thursday
PDC Energy Scheduled to Post Earnings on Thursday
Shell Midstream Partners  to Release Quarterly Earnings on Thursday
Shell Midstream Partners to Release Quarterly Earnings on Thursday
Q2 2018 Earnings Forecast for Cimarex Energy  Issued By Seaport Global Securities
Q2 2018 Earnings Forecast for Cimarex Energy Issued By Seaport Global Securities
Vulcan Materials  to Post Q2 2018 Earnings of $1.41 Per Share, Jefferies Group Forecasts
Vulcan Materials to Post Q2 2018 Earnings of $1.41 Per Share, Jefferies Group Forecasts
Telephone and Data Systems  Set to Announce Earnings on Thursday
Telephone and Data Systems Set to Announce Earnings on Thursday


© 2006-2018 Ticker Report. Google+.